Selective histone deacetylase inhibitors for the treatment of human disease
Selective HDAC inhibitors, and pharmaceutical compositions that include the same, are described herein for the treatment of cancer, immunological diseases, inflammatory diseases, and neurological diseases.
1. A compound of formula I, II, III, IV, or V:
wherein R 1 is H or optionally substituted alkyl or aryl;
R 2 is H or optionally substituted alkyl or aryl;
Q is a moiety selected from the group consisting of NR 3 —(CH 2 ) n —, —(CH 2 ) n —NR 3 —, NR 3 —C(═O)—(CH 2 ) n —, —(CH 2 ) n —C(═O)—NR 3 —, —C(═O)—NR 3 —(CH 2 ) n —, and —(CH 2 ) n —NR 3 —C(═O)—, wherein n is 0 or 1, and R 3 is H or optionally substituted alkyl or aryl;
each of R 4 , R 5 , R 6 , and R 7 are independently selected from the group consisting of H, halo, and optionally substituted alkyl, aryl, alkoxy, and aryloxy;
Z is O, S, S(═O), or S(═O) 2 ;
A is a moiety selected from the group consisting of
or a pharmaceutically acceptable salt, solvate, hydrate, cocrystal, or prodrug thereof.
2. The compound of claim 1 , wherein the compound is of formula (VI):
or a pharmaceutically acceptable salt, solvate, hydrate, cocrystal, or prodrug thereof.
3. The compound of claim 1 , wherein the compound is of formula (VII):
or a pharmaceutically acceptable salt, solvate, hydrate, cocrystal, or prodrug thereof.
4. The compound of claim 1 , wherein the compound is of formula (VIII):
or a pharmaceutically acceptable salt, solvate, hydrate, cocrystal, or prodrug thereof.
5. A pharmaceutical composition comprising a histone deacetylase (HDAC) inhibitor of claim 1 , or a pharmaceutically acceptable salt, solvate, hydrate, cocrystal, or prodrug thereof.